City of Hope opens multiple myeloma autologous CAR T-cell therapy trial targeting CS1 protein

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope is enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor T-cell therapy trial.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login